# Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

> **NCT00978432** · PHASE2 · TERMINATED · sponsor: **Anne Beaven, MD** · enrollment: 50 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** RAD001
- **DRUG:** LBH589
- **DRUG:** Doublet (RAD001 and LBH589)

## Key facts

- **NCT ID:** NCT00978432
- **Lead sponsor:** Anne Beaven, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2015-04
- **Final completion:** 2016-03
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** The toxicity seemed to outweigh the benefit.
- **Last updated:** 2016-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00978432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00978432, "Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00978432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*